Rafael Holdings, Inc. — Form 8-K
Filed September 30, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 72/100
What the filing says
Rafael Holdings announced September 30, 2026 topline results from its pivotal Phase 3 TransportNPC study of Trappsol Cyclo in 94 Niemann-Pick Disease Type C patients (63 drug, 31 placebo). The primary endpoint—change in 4DNPCSS at Week 96—did not achieve statistical significance (p=0.19), showing 64% slowing of disease progression. However, a prespecified subgroup analysis of 78 patients (83% of study population) on background miglustat and/or leucine therapy showed statistical significance (p=0.046) with 71% disease progression slowing. Company remains on track for NDA submission in Q4 2026 pending FDA review.
Why this rating
Primary endpoint failure is a material setback for a ~$39M market-cap biotech dependent on this asset. Partial salvage via subset analysis and prior survival data offer regulatory hope, but primary miss substantially reduces approval odds and commercial value.
Price action (we called it negative)
before filing · preread $1.30 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.